Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 19 years to 70 years old at time of study entry (consent)~2. Diagnosis of Multiple Myeloma as per updated International Myeloma Working Group (IMWG) criteria .~3. Must have measurable disease defined as: for secretory MM, serum monoclonal protein ≥1.0 g/dL, urine monoclonal protein ≥200 mg/24 hrs, and involved free light chain ≥ 10 mg/dL; or in case of non-secretory MM, bone marrow plasma cell percentage ≥30%.~4. Must have standard risk myeloma (see exclusion criterion 4).~5. Must have received bortezomib, lenalidomide and dexamethasone (VRd) as a form of induction therapy pre-AHSCT (use of cyclophosphamide, bortezomib and dexamethasone may be allowed for up to 2 weekly doses before initiation of VRd induction, if necessary clinically for cytoreduction)~6. Able to understand and sign a consent form.~7. Creatinine clearance equal or \> 60 ml/min (calculated)~8. Ejection fraction equal or \> 50% before admission for transplant as per institutional standards. Patients with coronary heart disease (recent myocardial infarctions, angina, cardiac stent, or bypass surgery in the last 6 months or arrhythmia) need to be cleared by cardiology as per institutional BMT standards.~9. Serum bilirubin, ALT, AST less than 3 X upper limit of normal~10. FVC, FEV1 or DLCO \>50% predicted before admission for transplant as per institutional standards. Patients on home oxygen are not allowed on the protocol.~11. No more than 6 months of pre-transplant MM chemotherapy is allowed (from the date of the start of the induction therapy).~12. KPS ≥ 70%or ECOG 0-2.~13. Must be eligible to receive Melphalan dose of 200mg/m2~14. A female of child-bearing potential, must have two negative urine pregnancy test results within 10 to 14 days prior to starting the first dose of vaccine pre-transplant as a way of ensuring safe transplant planning.~Exclusion Criteria:~1. Participation in another clinical study with an investigational product during the last 28 days.~2. Prior stem cell transplant (either autologous or allogeneic)~3. Creatinine clearance \< 60 ml/min (calculated)~4. High risk MM defined as those with the following disease, fluorescence in situ hybridization and/or cytogenetic features: del17p, del1p with 1q gain, t(4;14), t(14;16), t(14;20), \>1 cytogenetic abnormality on karyotype, hypodiploid, plasma cell leukemia (primary or secondary), or subjects who failed to achieve ≥PR to induction therapy (i.e. VRd) and required salvage induction prior to AHSCT.~5. Documented central nervous system or extramedullary disease.~6. Significant organ dysfunction deemed to carry inappropriate risk for AHSCT.~7. Intention or plans for cyclophosphamide mobilization.~8. Known allergic reactions after previous tetanus diphtheria vaccination or had a condition of Guillain Barre Syndrome (GBS)~9. Known active hepatitis B, C or HIV infections on initial assessment.~10. Enrollment on any other transplant related protocols.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (vaccine, CD34 transplant, DLI) (Type: EXPERIMENTAL): ARM I: Patients receive 3 doses of tetanus before transplant and on days 15, and 60 post transplant.
- Arm II (vaccine, stem cell transplant) (Type: ACTIVE_COMPARATOR): Patients receive 3 doses of tetanus as in Arm I. Patients receive high-dose melphalan IV on day -2 and undergo AHSCT on day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).